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INTRODUCTION
Agoraphobia is usually defined as a state of anxiety that de-
velops when someone is in public or crowded places and thinks 
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s/he cannot receive appropriate help when in need or cannot 
escape from when facing danger. Thus, people with agorapho-
bia strive to avoid such places or situations and tend to devel-
op intense anxiety when forced to do it. Until Diagnostic and 
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Objective   Current nosology redefined agoraphobia as an autonomous diagnosis distinct from panic disorder. We investigated the life-
time prevalence of agoraphobia, its association with other mental disorders, and its impact on the health-related quality of life (HR-QoL).
Methods   Community survey in 2,338 randomly selected adult subjects. Participants were interviewed with the Advanced Neuropsy-
chiatric Tools and Assessment Schedule (ANTAS), administered by clinicians. The diagnoses were based on the ICD-10 criteria. The 
Short-Form Health Survey (SF-12) was used to quantify HR-QoL.
Results   In the sample, 35 subjects met the criteria for agoraphobia (1.5%), with greater prevalence among women (2.0%) than men 
(0.9%): odds ratio (OR) 2.23; 95% CI: 1.0-5–2. Agoraphobia was more often seen among those with (n=26; 1.1%) than without (n=9; 
0.4%) panic disorder: OR=8.3; 2.9–24.4. Co-morbidity with other mental disorders was substantial. The mean score of SF-12 in people 
with agoraphobia was 35.2±7.8, with similar levels of HR-QoL in people with (35.3±7.9) or without (34.8±7.3) panic disorder: ANOVA: 
F(1;33)=0.0; p=1.00. 
Conclusion   One out of seventy people may suffer from agoraphobia in their lifetime. The attributable burden in terms of HR-QoL is 
substantial and comparable to the one observed for chronic mental disorders such as major depression, post-traumatic stress disorder, 
or obsessive-compulsive disorder. Psychiatry Investig
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Statistical Manual of mental disorders-fourth edition (DSM-
IV), agoraphobia was a qualifier of panic disorder.1 However, 
in the fifth revision of the diagnostic and statistical manual of 
the America Psychiatric Association, so-called DSM-5, agora-
phobia was granted a formal diagnosis, which can occur in-
dependently from any other anxiety disorder.2 The current defi-
nition of agoraphobia in DSM-5 assigns a prominent role in 
the diagnosis to marked fear or anxiety about actual or antic-
ipated exposure to public places or situations such as “using 
public transportation; being in open spaces; being in enclosed 
places; standing in line or being in a crowd; or being outside 
of the home alone in other situations” (DSM-5 code: 300.22).2 
Fear or anxiety must recur most of the time in at least two or 
more of the listed common situations. For the diagnosis, the 
individual must show both fears of exposure to public places 
and active avoidance of such situations. The fear or anxiety 
must not be related to a realistic threat or be explained by so-
ciocultural context, and it should be not a consequence of sub-
stance use or withdrawal from it. Six months or more of per-
sistent or recurrent symptomatology must be proved to make 
the diagnosis. On an epidemiological ground, the first age of 
diagnosis is relatively early: mid to late twenties. No specific 
“cause” has been identified for the onset of agoraphobia, but 
a set of risk factors tends to recur in the history of those who 
had received the diagnosis: besides genetic predisposition, the 
experience of grief or bereavement early in life, adverse or trau-
matic events during childhood, and parental overprotective-
ness are the most often cited. A history of childhood fears or 
night terrors is a frequent antecedent of agoraphobia in youths 
and adults.3 The estimated lifetime prevalence is around 1.3% 
and the incidence rate is 0.9% with no difference between men 
and women.4 There is no established treatment for agorapho-
bia. For mild forms of the disorder, cognitive-behavioral ther-
apy (CBT) is thought to be effective in alleviating symptoms 
and improving quality of life.5 For more severe variants, anti-
depressants are considered the first line of intervention.6 
Agoraphobia is currently separated from panic disorder.4,7 
The new category has made it possible to better define a non-
negligible share of people with agoraphobia without the panic 
disorder in the general population and to start defining ago-
raphobia as a disorder per se with a great impact on the well-
being of the individual regardless of the presence of the con-
comitance or not of panic disorder.4 However, even in the DSM-
5 era, there are no tools validated with these criteria in literature, 
and many studies of validation in languages other than English 
still are based on interviews that adopt the DSM-IV system.8,9 
The still-evolving long work of developing new diagnostic tools 
has not yet reached a point to allow the conduct of commu-
nity surveys with the new criteria.
The definition of agoraphobia in the tenth edition of the 
World Health Organization’s International Classification of 
Diseases (ICD-10), closely resembles the definition of the dis-
order of the DSM-5 (ICD-10 code: F40.0),10 albeit lacking the 
temporal restriction of six-month continuous active symptoms. 
Thus, it could be helpful to re-analyze the records of databas-
es of community studies already carried out using the ICD-10 
system for the diagnosis of anxiety disorders. 
This study aimed at investigating the prevalence, the demo-
graphic profile and the impact on the quality of life (QoL) of 
agoraphobia diagnosed according to the criteria of the ICD-10 
in a large and representative sample of the general population 
of Italy.
METHODS 
The study was approved by the by the ethical committee of 
the Italian National Health Institute (Rome) on August 21th, 
2010 and complied with the provisions of the Declaration of 
Helsinki of 1995 and its revisions.11 All participants signed a 
written informed consent. 
Design, participants and procedure
The data were drawn for the databank of a community sur-
vey.12 The study was aimed at evaluating appropriateness of 
drug prescription for the treatment of mental disorders in Italy, 
especially bipolar disorder, with a focus on antidepressants. The 
sample was randomly selected from the records of at least three 
municipalities (one urban, one suburban, and at least one ru-
ral) of six Italian regions. Those regions were selected as rep-
resentative of the geographic and economic characteristics of 
the whole set of Italian regions. Randomization was performed 
in eight cells obtained after stratification of the sample by gen-
der and age (four strata 18–24; 25–44; 45–64; >64). Invitation 
in the study was by contact with the relevant general practi-
tioners, who were initially asked to participate in the study and 
convey the invitation to their patients for survey collaboration. 
Thereafter, researchers contacted the participants by phone 
call and mail. Trained physicians or clinical psychologists car-
ried out the interviews, face to face in the subjects’ homes. Af-
ter the explanation of the finalities of the study and the aqc-
quisition of a written informeed consent, interviewers asked 
the interviewees to show them their drug boxes, if any, and 
were provided with a folder to retain all of the psychotropic 
drug box covers. Participants were then interviewed with a 
semi-structured interview and were requested to fill in some 
self-report questionnaires, including the Health Related (HR)-
QoL Survey Short Form. Whenever during the interview the 
participants had revealed symptoms related to a mental dis-
order under investigation, they received an appropriate referral 
to primary (general practitioner) or tertiary care (local psychi-
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1) The psychiatric interviews were conducted by means of 
Advanced Tools and Neuropsychiatric Assessment Schedule 
-Structured Clinical Interview (ANTAS).12 It is a semi-struc-
tured, full computerized interview derived in part from the 
SCID.13 ANTAS allows diagnosis of mood, anxiety and eating 
disorders according to DSM-IV-TR and ICD-10 with high re-
liability and cross-validity with SCID.12
2) The Health Related (HR)-QoL Survey Short Form (SF-
12)14 was used to assess perceived H-R-QoL as a measure of 
the impact of agoraphobia and the comorbid psychiatric con-
ditions The SF-12 allows to measure: physical health and func-
tionning, emotional condition, pain, general health status, vi-
tality, social funtiionning and mental wellbeing. The HR-QoL, 
as measured by the SF-12, is a construct that measures the sta-
tus and outcome of chronic diseases not only about the symp-
toms but also the relevant components of daily life.15
Definitions and subgroups
The diagnosis of major depressive disorder, post-traumatic 
stress disorders and anxiety disorders were defined according 
to ICD-10 criteria.10 All diagnoses were estimated as lifetime 
prevalence.
Statistical analysis
The odds ratio (OR) (univariate analysis) for ICD-10 agora-
phobia diagnosis and age, gender and comorbidity with ICD-
10 diagnosed disorders, was calculated using as a “pivot” one 
group by table. The χ2 test was used for measuring statistical 
significance. Miettinen’s simplified method was used for calcu-
lating Odds ratios and 95% confidence intervals.16 The SF-12 
scores by groups were compared by ANOVA one-way statistic.
The burden on the impairing HR-QoL “attributable” to ag-
oraphobia (attributable burden) was defined as the difference 
between HR-QoL (mean score on the SF-12) in the sample of 
people without agoraphobia and HR-QoL of people with ago-
raphobia (as mean score of SF-12) drawn from the community 
survey database. The control sample was obtained by random-
ization after blocks. For each person with agoraphobia, a cell 
selecting all the people without agoraphobia of the same age 
was carried out, thus four people were selected by random-
ization from each obtained cell.
The burden in worsening of HR-QoL attributable to ago-
raphobia was also compared to a similar meaure obtained to 
other diseases, in previous case-control studies that have ad-
opted the same database as sources of controls. 
In people with agoraphobia the number of those who sub-
mitted an SF-12 questionnaire score on quality of life below 35 
(poor HR-Qol) and above 38 (good HR-Qol) was also calcu-
lated; these cutt offs were suggested by the distribution of the 
score to the scale in the general population.17
RESULTS
The overall lifetime prevalence of agoraphobia was of 35 
cases out of 2338 people (1.5%). There were 26 cases with co-
morbid panic disorder and 9 cases without comorbid panic 
disorder. 
Table 1 showed lifetime prevalence of agoraphobia by sex 
and age, the prevalence was 0.9% in men 2.0% in women (OR= 
2.23; 95% CI: 1.0–5.2), no differences were found according 
to age distribution.
The cases of agoraphobia with panic disorder have higher 
lifetime prevalence than those without panic disorder (1.1% 
vs. 0.4% OR=8.3; 2.9–24.4) (Table 2), with no differences in 
distribution by gender and age in the subgroups of agorapho-
bia (with and without panic disorder), with a marginal rise 
among young people (OR=8.0; 0.9–73.4). 
Table 3 showed the association between agoraphobia and 
other anxiety disorders, major depressive disorder, and post-
traumatic stress disorder. Agoraphobia was often comorbid 
with major depressive disorder (OR=16.2; 7.3–35.6); panic 
disorder (OR=87.0; 37.3–208.2); simple phobia OR=7.7 (2.5–
21.9); social phobia OR=59.3 (12.6–271.3); generalized anxi-
ety disorder (OR=12.0; 4.5–30.6); obsessive-compulsive dis-
order (OR=7.1; 2.0–22.5); post-traumatic stress disorder (OR= 
9.2; 1.4–44.9). 
The co-morbidity with anxiety disorders, major depression 
and post-traumatic stress disorder was perfectly superimpos-
able in cases of agoraphobia with or without panic disorder 
(Table 4).
Table 1. Lifetime prevalence of agoraphobia by gender and age
N (%) χ2 (df=1) p OR 95% CI
<25 males 0 (0) -
25–44 2 (0.5) 0.001* 0.977 0.0 0–11.7
45–64 3 (1.0) 0.250* 0.617 0.0 0–5.2
>64 4 (2.1) 0.403* 0.235 0.0 0–2.14
Total males* 9 (0.9)
<25 females 3 (2.2) -
25–44 9 (2.0) 0.226 0.884 1.01 0.29–3.72
45–64 13 (2.7) 0.214 0.643 0.77 0.21–2.47
>64 1 (0.4) 0.242 0.875 0.91 0.22–3.34
Total females† 26 (2.0) 5.520 0.033 2.24 1.0–5.17
<45 vs. >44 in M+F 1.3 0.734 0.392 0.74 0.4–1.4
*with Yates’s correction, †female vs. males
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The mean score of SF-12 in people with agoraphobia was 
35.2±7.8, with similar levels of HR-QoL in people with (n= 
26) or without panic disorder (n=9): 35.3±7.9 vs. 34.8±7.3 
[ANOVA: F(1;33)=0.0; p=1.00]. As many as 14 out of 35 indi-
viduals diagnosed with agoraphobia (40%) had an SF-12 score 
higher than or equal to 39, which indicates a good level of HR-
QoL, while 16 (45.7%) had an HR-QoL level lower than 35 
(poor HR-QoL). Overall, agoraphobia showed an attributable 
burden comparable to that observed for the other investigat-
ed disorders (Table 5).
Table 5. Attributable Burden in worsening Quality of Life due to Agoraphobia and comparison with other disorders
SF-12 (mean±SD) Attributable burden due to the disorder ANOVA*
Agoraphobia 35.2±7.8 3.4±3.6 (N=35)
Major depressive disorder 33.8±9.2 5.6±3.6 (N=37) F(1;70)=6.6; p=0.012
Panic disorder 35.5±4.6 2.9±0.9 (N=123) F(1;156)=0.72; p=0.396
Simple phobia 35.8±6.1 2.5±2.4 (N=54) F(1;87)=2.48; p=0.119
Obsessive-compulsive disorder 35.4±6.9 2.9±6.0 (N=88) F(1;121)=0.21; p=0.646
Post-traumatic stress disorder 36.3±6.1 3.9±1.0 (N=26) F(1;59)=0.47; p=0.495
Attributable Burden=Quality of Life in a matching control group without Agoraphobia (matching controls 1/4 from the community). *com-
parison with agoraphobia without panic disorder. SD: standard deviation, N: number (i.e., sample size), SF-12: 12-item Short-Form Health 
Survey, ANOVA: analysis of variance





χ2 (df=1) p OR 95% CI
Males 5 (0.5) 4 (0.4) 0.294* 0.192 0.3 0.06–1.5
Female 21 (1.6) 5 (0.4)
<45 with vs. without 13 (1.2) 1 (0.1) 0.097* 0.056 8.0 0.9–73.4
>44 with vs. without 13 (1.0) 8 (0.6)
Total (1.5%) 26 (1.1) 9 (0.4) 14.63* <0.0001 8.3 2.9–24.4
*with Yates’s correction
Table 3. Comorbidity between agoraphobia and other disorders
Comorbid with agoraphobia (%) χ2 (df=1) p OR 95% CI
Major depressive disorder 12 (34.3) 96.63 <0.0001 16.2 7.3–35.6
Panic disorder 26 (74.2) 425.3 <0.0001 87.0 37.3–208.2
Simple phobia 5 (14.3) 17.51* <0.0001 7.7 2.5–21.9
Social phobia 4 (11.4) 86.66* <0.0001 59.3 12.6–271.3
Generalized anxiety disorder 7 (20.0) 47.3 <0.0001 12.0 4.5–30.6
Obsessive-compulsive disorder 4 (11.4) 12.27* <0.0001 7.1 2.0–22.5
Post-traumatic stress disorder 2 (5.7) 6.23* 0.0013 9.2 1.4–44.9
*with Yates’s correction





Fisher’ p OR 95% CI
Major depressive disorder 10 (47.6) 2 (22.2) 1.00 3.2 0.5–19.0
Simple phobia 4 (10.0) 1 (11.1) 1.00 1.8 0.2–19.9
Social phobia 3 (14.2) 1 (11.1) 1.00 1.3 0.1–14.9
Generalized anxiety disorder 5 (23.8) 2 (22.2) 1.00 1.1 0.2–7.1
Obsessive-compulsive disorder 3 (14.2) 1 (11.1) 1.00 1.3 0.1–14.9
Post-traumatic stress disorder 2 (5.7) 0 (0) 1.00 - -
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DISCUSSION
The lifetime prevalence of agoraphobia found by our study 
is in the range of the estimates found by studies that used DSM-
IV criteria for diagnosis or that have recalculated rates with 
DSM-5. The World Health Survey (WHS) found lifetime prev-
alence of agoraphobia of 1.4% according to DSM-IV criteria and 
1.5% according with those of DSM-5.4 The National Epidemi-
ologic Survey on Alcohol and Related Conditions (NESARC) 
had found in the US a lifetime prevalence of 1.3% (as a sum 
of panic disorder with agoraphobia and agoraphobia without 
panic disorder).18 In the same year and still in the US, the Na-
tional Comorbidity Survey Replication (NCS-R) had found a 
lifetime prevalence of panic disorder with agoraphobia of 1.1% 
and agoraphobia with panic disorder 0.8% according DSM-IV.19 
The prevalence of agoraphobia without panic disorder in 
the present study is in the range of previous studies conducted 
with the DSM-5: from 0.2% of NESARC to 1.0% of WHS. It 
is also not far from the results of a study carried out in Derry, 
North Irleand,20 which used a two phases design and found a 
lifetime prevalence of 0.7% of ICD-10 agoraphobia without 
panic disorder. As far as the specific prevalence of agoraphobia 
without panic disorder is concerned, our studies seem to be 
quite distant from almost all studies conducted using DSM-IV 
as a criterion and highly structured tools for diagnosis conduct-
ed by lay interviewers.21 However, in the European Study on 
the Epidemiology of Mental Disorders (ESEMeD) ther pooled 
data from France, Belgium, Spain, The Netherland and Italy 
showed a liferime prevalence of agoraphobia without panic 
disorder of 0.9%.22
Other studies found a higher prevalence than in the present 
study: Munchen Region, Germany (2.6%);23 Finland (0.7%);24 
Dresden, Germany (1.8%);25 The Netherland (1.6%);26 Oslo 
Norway (3.1%);27 Germany (2%).28 It should be noted, how-
ever, that the only study that used trained clinical interviewers 
(in Sesto Fiorentino, Italy), even with structured interviews 
and using DSM-IV as a criterion, lifetime prevalence figures 
were much lower than in the others DSM-IV surveys (0.4% 
versus, on average, 2.0%) and much closer to ours.29 In the WHS 
database, the comparison between the diagnoses of agora-
phobia without panic disorder carried out applying DSM-IV 
and DSM-5 criteria indicated that these two systems tend to 
identify different conditions under the same diagnosis.4 Con-
versely, the diagnoses that are done according to the criteria 
of the ICD-10 are closer to the ones that are based on the cri-
teria of the DSM-5.4 It should be borne in mind that the WHS 
study, lay interviewers applied a highly structured interview 
while in the present study clinicians used semi-structured in-
terviews. It is therefore possible that the more clinically orient-
ed method of this study has allowed a more accurate identifi-
cation of even the light forms of panic disorder (thus decreasing 
the quote of agoraphobia without panic disorder). In the past, 
the debate on the reproducibility of the diagnoses conducted 
with the semi-structured interviews was in fact the subject of 
a heated debate, especially regarding mood disorders, with ir-
reconciliable point of views.30,31
The two subgroups of agoraphobia with and without panic 
disorder found in the present study show a very similar pro-
file in terms of age and gender distribution, comorbidity with 
anxiety disorders, post-traumatic stress disorder, and major 
depressive disorder, as well as of the level of impairment of 
quality of life. These findings support the notion that agora-
phobia is a homogeneous group and not the confluence of two 
separate conditions.
As far as the level of impaiment due to agoraphobia is con-
cerned, the result can be considered partly unexpected. Ago-
raphobia is often thought to be a disabling disorder.32 However, 
in this study agoraphobia did not reach the HR-QoL impair-
ment level of the major depressive disorder, and its HR-QoL 
impairment was similar to the one observed for panic disor-
der, obsessive compulsive disorder, post-traumatic stress dis-
order, and specific phobia. In recent studies, the impact on HR-
QoL of major depressive disorder was found to be similar to 
the one produced by severe hematological cancers,33 and post-
traumatic stress disorder was found to impair HR-QoL more 
than panic disorder.34 Moreover, separate investigations have 
shown that the impaiment of quality of life attributable to the 
comorbidity with simple phobia depends on conditions in co-
morbidity and not on the disturbance itself.35 The findings are 
consistent with other studies that had seen the co-morbid ag-
oraphobic component affecting the quality of life in a measure 
not inconsistent with other anxiety disorders.36,37 Similarly, the 
impact on quality of life of obsessive-compulsive disorder was 
found to be influenced by the co-morbidity with bipolar spec-
trum disorders.38 
However, the attributable burden of agoraphobia is non-
negligible. When compared to the attributable burden of oth-
er chronic and disabling conditions in studies that applied the 
same methodology of this study, the attributable burden of ag-
oraphobia resulted higher than the attributable found in celi-
ac disease,39 lower than in multiple sclerosis,40 or in fibromyal-
gia,41 but comparable to the one observed for Wilson disease 
and eating disorders.42,43
Severe role impaiment was reported in WHS in arond 1/3 
of people diagnosed with agoraphobia. This seems to confirm 
that the share of people in the general population who receives 
a diagnosis of agoraphobia often presents severe impaiment 
(WHS) or a strong impairment of quality of life, but this does 
not apply to all people with agoraphobia equally. The percent-
age of people with strong impairment of quality of life identi-
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fied by our study on the total of people with ICD-10 agorapho-
bia (40%), seems much closer to the percentage of people with 
DSM-5 agoraphobia identified by WHS as suffering from a 
strong impairment (43%), which is a higher percentage of se-
vere impairment among people diagnosed with agoraphobia 
according to the criteria of the DSM-IV (30%). It should be 
noted that in this study women reported a higher prevalence 
of agoraphobia than men. Past studies found that women are 
more likely than men to stay at home to avoid agoraphobic 
situations and are also more likely to look for a companion to 
going outside.44 This may limit their capacity to optimally 
functioning and may have contributed to the relatively high 
percentage of participants with a strong impairment of quality 
of life in people that were diagnosed with ICD-10 agorapho-
bia in this study (40%).
Several limitations have to be acknowledged. The study was 
designed to investigate the prevalence of people diagnosed with 
the bipolar spectrum, who were estimated to be 4%, but ago-
raphobia has lower lifetime prevalence. Thus, the frequency of 
agoraphobia in the study was small, affecting the power to pre-
cisely estimate co-morbidity and associations among different 
disorders. Another limitation is that our study was conducted 
with a different methodology from most of the comparison 
epidemiological studies, with the use of clinical interviewers 
and with the ICD-10 diagnosis, which is not frequent in epi-
demiological studies.
The study seems to confirm a homogeneous profile in ago-
raphobia dependent on comorbidity of panic disorder; this 
profile concerns the associated conditions such as gender, age, 
anxiety and disorders in comorbidity and the impairment 
produced in quality of life. The disorder presents itself as a 
condition capable of producing a serious impairment of the 
quality of life but not in all the people affected by it.
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